Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the cheap US stocks to buy according to analysts. On November 18, Wolfe Research analyst Kalpit Patel initiated coverage of Soleno Therapeutics with an Outperform rating and $75 price target. The company’s shares showed recent weakness in the market due to a sequential slowing in the number of new patient starts. However, Patel noted that the market’s safety concerns surrounding this slowdown are considered overblown.

Based on the firm’s proprietary survey results, Patel maintains that the overall directional trend for patient utilization is highly favorable and is expected to continue for the next 1-2 years. This market outlook also aligns with the strong financial results recently reported by the company.

Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns

In its Q3 2025 earnings report, Soleno Therapeutics reported a positive net income of $26 million, driven by sharply increased sales of its drug, ViCAT XR. Total net revenue more than doubled from Q2 and reached $66 million. The growing market adoption of ViCAT XR is reflected by the fact that the company has secured broad coverage, encompassing ~132 million lives, and currently has 764 active patients on the drug, all of whom have claims being reimbursed.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of rare diseases.

While we acknowledge the potential of SLNO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLNO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.